ArticleMedicine2025
The cardiometabolic index as a predictor of sleep disorders and mortality: A cross-sectional study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Untargeted plasma metabolomics reveals systemic metabolic dysregulation and reatment-associated metabolic modulation following YWKS treatment in sleep disorder patients.Frontiers in pharmacology · 2026Article
- The Cardiometabolic Index (CMI) is associated with an increased risk of obstructive sleep apnea: a population-based study.European journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cardiometabolic index (CMI) reflects an individual's cardiometabolic health and is linked to the risk of dyslipidemia, obesity, hyperglycemia, and hypertension. These risk factors not only increase the likelihood of cardiovascular disease but are also strongly associated with sleep issues such as sleep apnea and insomnia. However, the relationship between CMI and the risk of sleep disorders remains unclear. This study aimed to investigate the association between CMI and sleep disorder-related morbidity and mortality. This cross-sectional study utilized data from 6220 adults aged ≥ 20 years from the National Health and Nutrition Examination Survey (2007-2014). The CMI was calculated as [waist circumference (cm)/height (cm)] × [triglycerides (mmol/L)/high-density lipoprotein-C (mmol/L)], reflecting metabolic risk. Participants were categorized into 3 CMI tertiles (Q1-Q3). Based on survey data, participants were classified into sleep disorder and non-sleep disorder groups. The analysis included logistic regression, subgroup analysis, forest plots, and survival analysis. The average age of participants was 49 ± 18.00 years; 49% were male. The high-CMI group had older participants, more males, higher body mass index, higher triglycerides, and more hypertension (P < .001). Higher CMI was significantly associated with an increased risk of sleep disorders (odds ratio [OR] = 1.11, 95% CI: 1.02 to 1.21, P = .017), with the prevalence being greater in Q3 than in Q1 (OR = 1.46, 95% CI: 1.27 to 1.68, P ≤ .001). After adjusting for demographics, the association persisted (OR = 1.13, 95% CI: 1.03-1.24, P = .014). The mortality rate was also higher in the high-CMI group (P≤.001), with a 34% increased risk of death (OR = 1.34, 95% CI: 1.08-1.67, P = .021). The study found that a higher CMI is associated with increased risks of sleep disorders and mortality. Understanding this relationship may help in monitoring cardiometabolic health and assessing sleep disorder severity. CMI could serve as a cost-effective indicator for sleep disorder assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.